Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Rhea-AI Summary

Cosmos Health CEO Greg Siokas has significantly increased his stake in the company by purchasing 1,466,764 common shares valued at $526,000 through five transactions between April 21-24, 2025. This recent investment brings his total beneficial ownership to 5,582,066 shares.

Over the past five months, Siokas has invested more than $1.3 million, adding over 2.7 million shares to his holdings. His total investment in the company since inception now exceeds $18 million.

As a vertically integrated global healthcare group, Cosmos Health focuses on:

• Innovative R&D
• Proprietary pharmaceutical and nutraceutical brands
• Healthcare product manufacturing and distribution
• Telehealth platform operations

The CEO expressed confidence in the company's direction and commitment to creating shareholder value.

Positive

• CEO increased ownership by 1.46M shares worth $526K in one week
• CEO invested $1.3M over past 5 months acquiring 2.77M shares
• CEO's total investment since inception exceeds $18M, showing strong insider confidence
• Company operates as diversified healthcare group with multiple revenue streams (R&D, pharmaceuticals, nutraceuticals, telehealth)

Negative

• None.

News Market Reaction

+3.49%

1 alert

+3.49% News Effect

On the day this news was published, COSM gained 3.49%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025.

As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health.

Greg Siokas, CEO of Cosmos Health, stated: “Over the past five months alone, I have invested more than $1.3 million, increasing my ownership by over 2.7 million shares and bringing my total investment since inception to more than $18 million. I am proud of what we have accomplished in building a diversified, vertically integrated global health care company, and I am more excited than ever about the opportunities ahead. I remain deeply committed to supporting Cosmos and confident in our efforts to create value for our shareholders.”

Information on Mr. Siokas’s Recent Transactions:
Please refer to the filings on Form 4 filed with the SEC and available on the SEC's website for more information about the nature of the transactions, including details such as “Ownership Form”, “Transaction Date”, “Amount”, “Price”, and other relevant information regarding the shares acquired by Mr. Siokas.

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653

FAQ

How many shares did Cosmos Health (COSM) CEO Greg Siokas buy in April 2025?

Greg Siokas acquired 1,466,764 shares valued at $526,000 through five transactions between April 21-24, 2025.

What is the total investment made by Greg Siokas in Cosmos Health (COSM) since inception?

Greg Siokas has invested more than $18 million in Cosmos Health since inception, with over $1.3 million invested in the past five months alone.

How many COSM shares does Greg Siokas own after April 2025 purchases?

After the April 2025 purchases, Greg Siokas beneficially owns 5,582,066 common shares in Cosmos Health.

What is the value of COSM shares purchased by Greg Siokas in the past 5 months?

Over the past five months, Greg Siokas acquired 2,777,469 shares in Cosmos Health for a total value of $1,325,000.

What is the average price per share paid by COSM CEO in April 2025 purchases?

Based on the 1,466,764 shares acquired for $526,000, the average price paid was approximately $0.36 per share.